Brief: Bliss GVS Pharma Says Rising Pharma Holdings Gets Final Approval From USFDA For Mesalamine Suppositories
15/04/2025 11:53
April 15 (Reuters) - Bliss GVS Pharma Ltd BLIS.NS: RISING PHARMA HOLDINGS GETS FINAL APPROVAL FROM USFDA FOR MESALAMINE SUPPOSITORIES Source text: [ID:] Further company coverage: BLIS.NS ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Bliss GVS Pharma
See all newsBrief: Bliss GVS Pharma June-Quarter Consol Net Profit 501 Million Rupees
Brief: Bliss GVS Pharma Appoints Rahul Adakmol As CEO Effective July 15, 2026
Brief: Bliss GVS Pharma Says Received Inspection Closure Report From World Health Organization
India's Bliss GVS Pharma gains on Anupam Rasayan's plan to buy stake
Brief: Bliss GVS Pharma Dec-Quarter Consol Net Profit 232.7 Million Rupees